Skip to main content

Table 3 Relationships between the protein expressions and clinicopathological factors in early-stage diseases

From: Differential roles of the Wip1–p38–p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas

Stages I–II (n=102) P53   Phospho-p53   Wip1   Nuclear phospho-p38   Cytoplasmic phospho-p38  
  Positive Negative   High Low   High Low   High Low   High Low  
  n=21 n=81 p-value n=57 n=45 p-value n=18 n=84 p-value n=50 n=52 p-value n=9 n=93 p-value
Age ≥60 4 (19%) 23 (28%) 0.58 13 (23%) 14 (31%) 0.37 7 (39%) 20 (24%) 0.24 13 (26%) 14 (27%) 1 3 (33%) 24 (26%) 0.70
FIGO stage I 17 (81%) 65 (80%) 1 48 (84%) 34 (76%) 0.32 14 (78%) 68 (81%) 0.75 44 (88%) 38 (73%) 0.081 9 (100%) 73 (78%) 0.20
Pure histology 21 (100%) 78 (96%) 1 55 (96%) 44 (98%) 1 17 (94%) 82 (98%) 0.45 49 (98%) 50 (96%) 1 8 (89%) 91 (98%) 0.24
Positive peritoneal cytology 7 (33%) 24 (30%) 0.79 23 (40%) 8 (18%) 0.017 1 (6%) 30 (36%) 0.011 18 (36%) 13 (25%) 0.28 4 (44%) 27 (29%) 0.45
Endometriosis present 13 (62%) 45 (56%) 0.63 37 (65%) 21 (47%) 0.073 13 (72%) 45 (54%) 0.19 29 (58%) 29 (56%) 0.84 5 (56%) 53 (57%) 1
Residual tumor present 0 (0%) 2 (2%) 1 1 (2%) 1 (2%) 1 0 (0%) 2 (2%) 1 1 (2%) 1 (2%) 1 0 (0%) 2 (2%) 1
Lymphadenectmy undone 2 (10%) 13 (16%) 0.73 6 (11%) 9 (20%) 0.26 4 (22%) 11 (13%) 0.30 5 (10%) 10 (19%) 0.26 1 (11%) 14 (15%) 1
Adjuvant chemotherapy performed 19 (90%) 76 (94%) 0.63 53 (93%) 42 (93%) 1 17 (94%) 78 (93%) 1 47 (94%) 48 (92%) 1 8 (89%) 87 (94%) 0.49
  1. FIGO International Federation of Gynecology and Obstetrics